Harris DE, Lacey A, Akbari A, et al. - Within a retrospective observational population cohort, researchers analyzed patients (n = 2,090) (2011–2015) who were advised for clopidogrel for 12 months (+aspirin) following the percutaneous coronary intervention, to determine the early discontinuation rate of P2Y₁₂ antagonists post-intervention, to define factors related to early discontinuation, to assess the risk of major adverse cardiovascular events (death, acute coronary syndrome, revascularization, or stroke) related to discontinuation from a prespecified prescribing instruction of 1 year. Early discontinuation was independently predicted by prior revascularization, prior ischemic stroke, and age > 80 years. The factors that independently predicted major adverse cardiac events in a time-dependent multiple regression model were clopidogrel discontinuation and bleeding, as well as age < 49 and ≥ 70 years (vs those aged 50–59 years), hypertension, chronic kidney disease stage 4+, prior revascularization, ischemic stroke, and thromboembolism. In the first year after the intervention, low discontinuation of clopidogrel was reported where a clear discharge instruction to treat for 1 year was given. Whereas this is reassuring from the population level, an increased rate of adverse events, most prominently in those with both bleeding and discontinuation, was observed in relation to discontinuation earlier than the intended duration, at an individual level.